TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01944202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational and feedback intervention, as described in the Arm Description.
Study: NCT00817557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol
Description: Anti-inflammatory

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rewetter
Study: NCT02247440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon + ribavirin under HIV physician supervision
Description: Peg-interferon + ribavirin under HIV physician supervision
Study: NCT02181582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapunil
Description: Single peroral administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Description: Positron emission tomography, which creates images by detecting radioactivity.
Study: NCT02655991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Case Monitoring
Description: Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
Study: NCT02014493

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannulae (HFNC)
Description: HFNC 6 l/pr.min

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP 6 l/pr.min
Study: NCT01054274

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: novel stent
Description: Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional covered stent
Description: Patients undergo placement of a conventional covered stent on day 1.
Study: NCT02005692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynaSense sensor
Study: NCT04533412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management barrier support
Description: For the intervention, community health workers will assess barriers to good self-management behaviors that lie within 4 domains: 1) social context, 2) physical health and functioning, 3) cognitive factors, and 4) psychological factors. They will work with participants for 6 months to help them work through their barriers to self-management of COPD. Participants can also participate in home-based pulmonary rehabilitation and can receive emergency pack/action pack medication for COPD exacerbations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic COPD Education
Description: The attention control will consist of 4 visits by a COPD educator to the home to review the COPD education booklet. During the first visit, this COPD educator will review the COPD 1-2-3 booklet in its entirety with the patient. During visits 2 and 3, the COPD educator will make a visit to check in with the patient, ask how they are doing with their respiratory symptoms, and review any sections of the COPD 1-2-3 booklet the patient chooses. The COPD educator will recommend visits every 2 months but the patient and COPD educator may choose to modify the interval as needed. If the patient appears to be experiencing worsening respiratory symptoms during any visit, the COPD educator will notify the patient's physician.
Study: NCT01672710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plain crystalline niacin, exercise, sauna
Description: A four to six week regimen consisting of daily, supervised, mild-moderate exercise as tolerated for 20 minutes, supervised, intermittent Finnish saunas (at about 140'F) sauna time with breaks and showers, gradually increased as tolerated to approximately 4 hours, dietary supplements including immediate release niacin in gradually increasing doses from 100 mg to a maximum of 5000 mg per day, salt and water, other vitamins, minerals and oils per Hubbard protocol.
Study: NCT02539043

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LIPOFOCUS
Description: In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 Megahertz (MHz), and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LIPOFOCUS
Description: In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 MHz, and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random . The procedure is followed by stereodynamic drainage, where it will be used a printhead comprising three ERAs (effective radiation area) of 15 Watt each time this procedure is calculated through the area (size of the area to be treated) divided by ERA (cm² head size).
Study: NCT03221855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidone
Description: Capsules 10mg orally each 8 hours for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules 10mg orally each 8 hours for 7 days.
Study: NCT04392778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC Treatment
Description: Protocol length: 1 week~Doses:~1. Application: 3 million cells/kg IV-------------------------------------------------0 day~2. Application: 3 million cells/kg IV ------------------------------------------------3rd day~3. Application: 3 million cells/kg IV -------------------------------------------------6th day~will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Saline Control
Description: Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.
Study: NCT02238002

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: The patients of both groups underwent cataract surgery

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: The patients of both groups underwent cataract surgery
Study: NCT01875380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Study: NCT01013610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNK-754
Description: Escalating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating dose
Study: NCT03203655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareMessage™
Description: Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Condition
Description: Control condition will receive an initial talk about weight loss but will not be enrolled in any program or intervention.
Study: NCT01744886

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maintain oxygenation during one lung ventilation
Description: All study patients will be placed on a volume controlled mode of ventilation with the following settings: tidal volume between 5 and 10 ml/kg and FIO2 at 50% and 4 cm H2O PEEP. Respiratory frequency and tidal volume will be adjusted to maintain ETCO2 between 30 and 40 mmHg. ETCO2 levels and SpO2 will be monitored continuously.~If SpO2 declines below 90% the ventilator settings will be adapted according to the following protocol: First the FIO2 is increased to 80%. If this is insufficient FIO2 is increased to 100%. If this remains insufficient 5 cm H2O of CPAP is applied to the non-ventilated lung. If this is still insufficient the surgeon will be asked to allow for temporary recruitment of the non-ventilated lung.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maintain oxygenation during one lung ventilation
Description: All study patients will be placed on a volume controlled mode of ventilation with the following settings: tidal volume between 5 and 10 ml/kg and FIO2 at 50% and 4 cm H2O PEEP. Respiratory frequency and tidal volume will be adjusted to maintain ETCO2 between 30 and 40 mmHg. ETCO2 levels and SpO2 will be monitored continuously.~If SpO2 declines below 90% the ventilator settings will be adapted according to the following protocol: First the FIO2 is increased to 80%. If this is insufficient FIO2 is increased to 100%. If this remains insufficient 5 cm H2O of CPAP is applied to the non-ventilated lung. If this is still insufficient the surgeon will be asked to allow for temporary recruitment of the non-ventilated lung.
Study: NCT04336748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: low dose (200mg) Hydroxychloroquine once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00983632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective vagus nerve stimulation
Description: Stimulus will be combination of quasi-trapezoidal cathodic and rectangular anodic current pulses. Precisely, the resulting current, biphasic and charge balanced combination will be composed of a quasi-trapezoidal cathodic phase with a square leading edge with different intensity ic , a plateau tc of 300 μs, and exponentially decaying phase texp of 500 μs, followed by a wide rectangular anodic phase ta of allow current magnitude ia. Anodic phase ia will be one-tenth of the magnitude in the cathodic phase. However, the width of the anodic phase ta will be dependent upon the charge injected in the cathodic phase: the greater the charge, the wider the anodic phase.~For details see detailed study description

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: selective vagus nerve stimulation
Description: electrical vagus stimulation
Study: NCT03435575

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boosth
Description: Boosth activity tracker which measures steps
Study: NCT01111838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Description: Patients will be enrolled and receive 200mg/m2 of STA-9090. Patients will receive single agent STA-9090 intravenous (I.V.) infusion (an indwelling catheter may not be used) over 60 minutes weekly (three weeks on and one week off). Follow-up imaging will be performed every 8 weeks to evaluate response.
Study: NCT02767063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade \>1 related AE.
Study: NCT01775215

Intervention type: OTHER
Intervention: Brain Natriuretic Peptide
Study: NCT03777475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transarterial infusion
Description: transarterial infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial infusion
Description: transarterial infusion
Study: NCT00528281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
Study: NCT03301675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange Juice (500 mL/d)
Description: Nutritionists prescribed the same balanced diet for both groups keeping suffice energy to maintain the current weight, estimated from total energy expenditure (TEE) for each individual and based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ/ banana or other fruits and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were colected every two weeks; blood samples and dietary questionnaires, monthly.
Study: NCT02767063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
Study: NCT01291147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivicaine
Description: levobupivicaine 0.5% continous infusion for 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: 0.9% saline continous infusion for 48 hours
Study: NCT03486613

Intervention type: OTHER
Group type: OTHER
Intervention: PROM registration via the DANBIO App on a smartphone
Description: PROM data is reported through the DANBIO smartphone app

Intervention type: OTHER
Group type: OTHER
Intervention: PROM registration via the DANBIO App on a smartphone
Description: PROM data is reported through the DANBIO smartphone app

Intervention type: OTHER
Group type: OTHER
Intervention: PROM registration via the touch screen solution
Description: PROM data is reported through the touch screen solution
Study: NCT03319784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
Study: NCT03486613

Intervention type: OTHER
Group type: OTHER
Intervention: PROM registration via the touch screen solution
Description: PROM data is reported through the touch screen solution
Study: NCT02343120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Oral administration by capsule
Study: NCT01945749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraarticular steroid
Description: 1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular saline
Description: 1 ml isotonic saline mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: The exercise is commenced 2 weeks after injection.~The exercise includes a 10 minute warm up phase (ergometer bicycling) followed by strengthening and coordination exercises focusing on trunk, hip and knees.~In case of pain or symptom exacerbation, a rescue exercise program is administered, excluding weight bearing activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: The exercise is commenced 2 weeks after injection.~The exercise includes a 10 minute warm up phase (ergometer bicycling) followed by strengthening and coordination exercises focusing on trunk, hip and knees.~In case of pain or symptom exacerbation, a rescue exercise program is administered, excluding weight bearing activities.
Study: NCT01314742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotene OralBalance® gel
Description: Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Water moisten cotton tipped applicator
Description: One oral care application will be performed every 4 hours, or at touch times, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
Study: NCT02219191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: puerarin tablet 50 mg
Study: NCT01672710

Intervention type: DRUG
Group type: OTHER
Intervention: plain crystalline niacin, exercise, sauna
Description: A four to six week regimen consisting of daily, supervised, mild-moderate exercise as tolerated for 20 minutes, supervised, intermittent Finnish saunas (at about 140'F) sauna time with breaks and showers, gradually increased as tolerated to approximately 4 hours, dietary supplements including immediate release niacin in gradually increasing doses from 100 mg to a maximum of 5000 mg per day, salt and water, other vitamins, minerals and oils per Hubbard protocol.
Study: NCT03013907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPLIFT
Description: Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping \& Relaxing Session 4: Attention \& Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure \& the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study
Study: NCT02893150

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: TAU (Treatment as Usual), individuals presenting with overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, teams of primary care (PC) organized care plans to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²).~For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities, evaluates the need for individual dietary prescription by the nutritionist. This decision is discussed among the team of PC and Matrix support team
Study: NCT04012515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrode Pads
Description: Participants wear six electrode pads in total; three different types of pad, worn in the same positions on both sides of the face. The pads on the left-hand side of the face are replaced daily, and those on the right-hand side are replaced every other day. The pads do not administer a medical treatment or perform any other active function. The purpose of the intervention is to determine which combination of pad and replacement regime maximises the tolerability of wear over a 30-day period.
Study: NCT03839654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
Study: NCT02893150

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU+MBHP
Description: TAU (Treatment as Usual) + MBHP. We used a general (general vulnerability, not specific) mindfulness-based intervention (MBI) developed by our research group, an 8-week-group-based MBI called Mindfulness-Based Health Promotion (MBHP) program . It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems, which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice; more feasible to be implement in health services and facilities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU+MB-EAT
Description: TAU (Treatment as Usual) + MB-EAT (mindfulness-based eating awareness training). Adapted from the MBSR, Mindfulness-based Eating Awareness Training (MB-EAT) or awareness training. This program was specially developed for the compulsive eating disorders and related problems\[47\]. In addition the four main techniques of meditation mentioned in the MBHP program includes modifications to these basic techniques, and include experimentation with different flavors, sweet and savory foods, etc. Has 10 weekly sessions of 2,5h
Study: NCT02418390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prophylactic central lymph node dissection
Description: dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
Study: NCT01002430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF-D gene transfer
Description: Gene transfer will be performed by using endocardial injection system (NOGATM) and an escalating dose of 1x109, 1x1010 and 1x1011 vpu of AdVEGF-D will be injected into 10 sites of the myocardium (0.2 ml per site).
Study: NCT04102748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: I-incision, M-flap and conventional implant exposure techniques
Description: Implant uncovering in the second stage using 3 different exposure techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: I-incision, M-flap and conventional implant exposure techniques
Description: Implant uncovering in the second stage using 3 different exposure techniques
Study: NCT05160324

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal of axillary lymph nodes.
Description: Axillary dissection in patients with positive sentinel lymph node

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preservation of axillary lymph nodes
Description: Preservation of axillary lymph nodes in patients with positive sentinel lymph node
Study: NCT02577055

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: myomectomy
Description: Surgical ablation of all fibroids

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolisation
Description: Embolisation of the peri-myoma vascular network, with non-resorbable particles of \>500 µm diameter, using an ultra thin catheter introduced through the vascular network up to the uterine arteries under radioscopic control.